ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors.

By J. C. Rodríguez-Manzaneque, Jennifer Westling, S. Thai, A. Luque, V. Knäuper, Gillian Murphy, J. Sandy, M. Luisa Iruela-Arispe. 2002

239 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

A Disintegrin and Metalloproteinase (ADAM) and ADAM with Thrombospondin Motifs (ADAMTS) Family in Vascular Biology and Disease (2019, background): “The function of ADAMTS-1 can be suppressed by TIMP-2 and 3, but is not affected by TIMP-1 and 4 [57].”
The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family (2015, background): “The aggrecanase activity of ADAMTS1 is inhibited by both TIMP-2 and −3, but not by TIMP-1 and −4 [36].”
Biosynthesis and Expression of a Disintegrin-like and Metalloproteinase Domain with Thrombospondin-1 Repeats-15 (2013, background): “The ADAMTS15 zymogen is processed extracellularly, similar to ADAMTS5 and ADAMTS9 (5, 6), and in contrast to ADAMTS1 and ADAMTS4, which are both activated intracellularly (8, 10, 34).”
Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease. (2018, background): “…metalloproteinase inhibition profile including ADAM-10, ADAM-12, and ADAM-17 as well as a disintegrin and metalloproteinase with thrombospondin motif ADAMTS-1, ADAMTS-2, ADAMTS-4 and ADAMTS-5 (Amour et al., 2000; Kashiwagi et al., 2001; Rodriguez-Manzaneque et al., 2002; Jacobsen et al., 2008).”